MorphoSys AG buy mohabbatein
Summary
This prediction ended on 22.11.13 with a price of €55.24. The BUY prediction by mohabbatein finished with a performance of 4.19%. mohabbatein has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | - | - | - | - |
iShares Core DAX® | 1.560% | 2.566% | 18.261% | 16.927% |
iShares Nasdaq 100 | 0.517% | 1.894% | 25.521% | 35.441% |
iShares Nikkei 225® | 1.730% | 5.631% | 18.569% | 13.063% |
iShares S&P 500 | 1.482% | 1.594% | 24.989% | 38.339% |
Comments by mohabbatein for this prediction
In the thread Morphosys AG diskutieren
Sippenhaft?
Wird Morphosys da in Sippenhaft genommen, für die (überinterpretierten) Zahlen von Evotec heute?
Wie dem auch sei: Hier scheint nun eine schöne Einstiegsgeelegenheit gekommen zu sein.
STRONG BUY.